to reconstructive surgery. In addition, we recommend prosthetic interposition grafts for major and patching of the aorta for minor abdominal aortic stenosis.
creatinine >2 mg/dL) who underwent percutaneous transluminal renal angioplasty (PTRA) with stenting for atherosclerotic RAS. In addition, in 100 patients with RAS and coexistent HF, we compared the impact of medical treatment (n = 50) versus PTRA (n = 50) on clinical outcomes. Results. HF (predominantly normal ejection fraction) was present in 50/163 (31%) patients with systemic hypertension and chronic kidney disease (serum creatinine >2 mg/ dL) undergoing PTRA for RAS and represented the major predictor of all-cause mortality in these patients. When compared with sex-matched RAS and HF patients treated medically, PTRA with stenting was associated with a significant decrease in the New York Heart Association Functional Class (1.9 ± 0.8 versus 2.6 ± 1.0, P < 0.04) and a 5-fold reduction in the number of hospitalizations. However, renal artery revascularization did not impact mortality. Conclusion. HF was present in one-third of patients with renal dysfunction and atherosclerotic RAS who were referred for PTRA. The presence of HF was associated with a significantly increased risk of death after PTRA with stenting. Renal artery revascularization resulted in improved HF control and a reduction in HF hospitalizations.
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Introduction
Atherosclerosis and systemic hypertension are common causes of heart failure (HF) [1] [2] [3] . Renal artery stenosis (RAS) is strongly associated with cardiovascular morbidity and mortality in patients with atherosclerotic disease [4] [5] [6] [7] and may impact the pathogenesis and control of HF. RAS has been associated with frequent abnormalities in left ventricular structure and function, acute episodes of left ventricular failure ('flash' pulmonary oedema), often mediated through labile systemic hypertension and exacerbation of myocardial ischaemia [8] [9] [10] [11] [12] [13] [14] [15] . It may also limit medical options for HF therapy, specifically the use of modulators of the renin-angiotensin-aldosterone system in patients with global ischaemia (caused by either bilateral RAS or stenosis to a solitary kidney), due to their potential to cause a simultaneous fall in glomerular filtration rate. Progressive RAS may contribute to chronic kidney disease, a major determinant of outcome in patients with HF [16, 17] . Yet, whether renal artery revascularization affects the outcome in patients with HF remains ill defined, with data limited to case reports or small uncontrolled case series [10, 12, 18, 19] . Despite this limited available evidence, 'flash pulmonary oedema, recurrent episodes of congestive HF or the inability to use modulators of the reninangiotensin system' are commonly accepted indications for renal artery revascularization [20] .
The objectives of this study were to (1) evaluate the prevalence, characteristics and significance of HF in a cohort of patients with significant atherosclerotic RAS and (2) assess the impact of percutaneous transluminal renal angioplasty (PTRA) with stenting on HF outcomes in patients with atherosclerotic RAS.
Methods

Subjects
All patients agreed to the use of their data for research purposes, and the study was approved by the Mayo Foundation Institutional Review Board. This retrospective design had two parts: firstly, the prevalence of HF was studied in patients who underwent PTRA with stenting at the Mayo Clinic for American College of Cardiology/American Heart Association (ACC/ AHA) with Class IIa indications of either accelerated or medically resistant hypertension or presumed ischaemic nephropathy (progressive renal disease in the setting of significant bilateral RAS or stenosis to a solitary kidney) [20] . Secondly, renal and cardiovascular outcomes in a subset of patients with both HF and renovascular disease who underwent PTRA with stenting were compared to those of a sex-matched group of control patients who had both conditions, but were treated medically at our institution. For each patient who underwent PTRA with stenting, a respective control was identified based on a diagnosis of RAS within 3 months of the procedure. All subjects had at least moderate renal impairment (National Kidney Foundation stage 3-5 chronic, non-dialysis dependent, kidney disease) [21] . Relevant clinical data were abstracted from medical records, which included documentation of outpatient, inpatient and emergency room visits at the Rochester Mayo Clinic, as well as correspondence from other medical providers.
Interventional technique
PTRA was performed using standard techniques. Arterial access was obtained with 5F or 6F intra-arterial sheaths by using the modified Seldinger technique, with the right femoral artery as the preferred access site. Renal artery stenting was performed after aortography and selective renal angiography, typically for stenoses exceeding 70% of the diameter or for a pressure gradient of at least 10 mmHg across the stenotic lesion. All patients underwent heparin infusion to achieve an activated clotting time of at least 200 s during the stent placement. Technical success was defined as a post-interventional residual stenosis <20%.
Clinical factors
Average blood pressure values obtained during outpatient visits were used for this analysis. Hypertension was defined as the presence of a persistent systolic blood pressure >140 mmHg, a diastolic blood pressure >90 mmHg or the use of medication for the treatment of elevated blood pressure [22] . RAS was diagnosed in the setting of accelerated or medically resistant systemic hypertension and/or presumed ischaemic nephropathy [20] , and the presence of a high-grade (>70%) stenosis of at least one renal artery on magnetic resonance angiography or conventional angiography [20] . For the purposes of this study, a diagnosis of HF was defined as the presence of both a clinical diagnosis of HF and fulfillment of standard Framingham HF criteria [23] .
Echocardiography was performed by experienced sonographers and reported by staff cardiologists with advanced training in echocardiography. All echocardiographic data used in the current study were recorded by the reviewing cardiologist at the time the scan was performed, and echocardiograms were performed according to American Society of Echocardiography guidelines [24] . Left ventricular systolic function was assessed semi-quantitatively using a visually estimated ejection fraction (EF). For the purposes of this study, reduced ejection fraction HF was defined as HF occurring in the setting of a left ventricular ejection fraction (LVEF) <40% at any time preceding a HF diagnosis. Assessment of diastolic function incorporated available measures of left atrial volume, pulse-wave Doppler of mitral inflow and pulmonary vein flow, pulsed-wave tissue Doppler of the medial mitral annulus and the determination of blood flow propagation within the left ventricle by colour M-mode. Diastolic function was graded as normal; grade 1 (mild dysfunction, delayed relaxation mitral inflow pattern); grade 2 (moderate dysfunction, pseudo-normal mitral inflow pattern) or grade 3 (severe diastolic dysfunction, restrictive mitral inflow pattern) [25, 26] .
Coronary artery disease was defined as a history of myocardial infarction, history of percutaneous or surgical coronary artery revascularization, stenosis >70% in at least one epicardial vessel on coronary angiography or the presence of ischaemia in 3 or more of 16 segments on stress echocardiography or stress nuclear testing.
To assess the impact of revascularization in patients with RAS and HF, we performed a matched cohort analysis with control subjects who were treated medically and were matched for sex and time of the procedure for those who underwent revascularization. Glomerular filtration rate (GFR), calculated from the modified Modification in Diet in Renal Disease (MDRD) equation [27] , was used as the primary measure of renal function. Improvement or worsening in renal function was defined as a 20% increase or decrease in GFR, respectively. Stable renal function was defined as a GFR on the last follow-up that, in comparison to a pre-intervention value, does not either increase or decrease by more than 20%.
The long-term follow-up of blood pressure, HF and renal function outcomes were ascertained as of the last available clinic visit. For patients whose mortality status was not available from the records (<5%), the National Death Index was used.
Statistical analysis
Statistical analyses were performed using JMP version 7.0 (SAS Institute Inc., NC) and are presented as mean ± standard deviation or median with inter-quartile range (IQR), as appropriate. The mean difference between groups is expressed with 95% confidence intervals. Statistical procedures included simple correlation analysis, analysis of variance, paired t-test, chi-square analyses, Kaplan-Meier survival analysis, proportional hazards and bi-variate fitting with simple linear regression. A P < 0.05 was predetermined.
Results
Prevalence of HF in patients undergoing renal artery revascularization
Of 163 consecutive patients who underwent PTRA with stenting for the treatment of hypertension in the setting of significant renal insufficiency (serum creatinine >2 mg/ dL), 50 (31%) fulfilled both clinical and Framingham criteria for HF. For no patient was HF the only indication for referral for intervention. Overall clinical characteristics were similar between patients with and without HF (Table  1) . Age, sex, renal function and blood pressure were similar, although those with HF were on a higher number of antihypertensive medications (Table 1 ). The prevalence of diabetes mellitus in patients with HF was 46% and 34% in those without HF, P = 0.08. The frequency of coronary artery disease, albeit high in both patient groups, either with (74%) or without (65%) HF, was not different between the groups (P = 0.5). Left ventricular systolic function was similar between the groups, with the majority of HF patients having a normal LVEF (Table 1 ). In the subgroup of patients who had full trans-thoracic echocardiograms with diastolic function assessments, the prevalence of diastolic function abnormalities was high in all patients. However, there was a difference in the degree of diastolic function abnormalities between those with and without HF, with a much greater prevalence of severe abnormalities in those patients with HF (Table 1) , including a larger left atrial size and a greater prevalence of echocardiographic evidence of elevated left ventricular filling pressures (E/e′ >15), 89% versus 39%, respectively (P < 0.0001). Patients with HF also had a significantly greater LV mass.
Association of HF with mortality following renal artery revascularization
Mortality was high in patients following PTRA with stenting, with a median survival of 58.2 months [lower and upper confidence intervals (CI): 51.7-80.8 months]. The presence of HF was associated with a significantly increased risk of death on follow-up ( Figure 1) , with an age and sex-adjusted risk ratio (RR) of 2.9, CI 1.8 -4.8, P < 0.0001. The estimates for mortality at 1 and 5 years for patients with HF were 23% (15-32) and 73% (58-83), respectively, compared to those without HF 8% (5-13) and 35% (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) , respectively (P < 0.0001). Other factors that were associated with mortality included serum creatinine (RR per mg/dL of 2.7, CI 1.1-6.3, P < 0.05). After also adjusting for renal function, HF remained significantly associated with mortality (RR 3.4; CI 2-5.7; P < 0.0001). HF, heart failure; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; RAS, renal artery stenosis; LVEF, left ventricular ejection fraction; E/e′, Ratio of Doppler derived peak mitral inflow velocity (E) to tissue Doppler derived medial mitral annulus peak diastolic velocity (e′). Fig. 1 . In a cohort of patients with atherosclerotic RAS undergoing percutaneous renal artery revascularization, heart failure is associated with increased long-term mortality (P < 0.0001).
Diabetes mellitus, hypertension and coronary disease were not associated with increased mortality. After adjusting for age, sex and baseline renal function, the presence of HF was also associated with an increased risk of progression to dialysis or renal transplantation upon follow-up (RR 2.3; 1.1-5; P < 0.05). HF was a major predictor of death whether there was significant unilateral (RR 3.65, P < 0.01) or bilateral (RR 2.65, P < 0.005) RAS.
Comparative analysis of patients with RAS and HF
Patients who underwent PTRA with stenting for atherosclerotic RAS and had HF were matched one-for-one with patients with atherosclerotic RAS managed medically on the basis of the date of RAS diagnosis and sex. Baseline demographics are listed in Table 2 . HF patients who were managed medically tended to be older, but blood pressure, medication usage and comorbidities were similar (Table 2) . There was no difference in the degree of renal dysfunction between the medically managed and renal artery revascularization groups. Baseline 24-h proteinuria, 249 (IQR 107-890) versus 167 (IQR 71-563) mg, and GFR (40 ± 21 versus 37 ± 18 mL/min/m 2 ) were similar.
The severity of HF symptomatology was comparable: 47/50 in the intervention group and 42/50 in the control group were symptomatic with NYHA class II or higher. Also, the proportion of patients with New York Heart Association (NYHA) Class III or IV HF was similar between the groups (Table 2) . With respect to the type of HF, while the majority had coronary disease, the average LVEF was preserved (Table 2) . Between the date of RAS diagnosis and last available follow-up, the frequency of other cardiovascular interventions was similar between the groups (Table 3) .
Renal artery revascularization, blood pressure control and renal function
At the time of RAS diagnosis, the severity of hypertension and the number of antihypertensive medications used were not different between patients who subsequently underwent PTRA and those who were treated medically ( Table 2 ). Over a mean clinical follow-up of 33 ± 9 months, renal artery revascularization was associated with better blood pressure control (Figure 2A and B). Those RAS/HF patients who underwent PTRA with stenting on average had a greater reduction in systolic blood pressures (−28 ± 24 mmHg versus −9 ± 27 mmHg, P < 0.01) and fewer numbers of antihypertensive medications (−0.6 ± 1 versus 0.2 ± 0.7, P < 0.01) (Figure 2A and B) . There was no overall difference in the rate of decline in renal function seen in both groups, ( Figure 2C ). Rates of acute kidney injury and progression to end-stage renal disease requiring renal replacement therapy were similar (Table 3) . However, more patients in the intervention cohort improved their renal function (13 versus 4, P < 0.04) ( Table 3 ). In those patients who had a LVEF <40% and who under- went PTRA with stenting, there was a significant increase in the number of patients who were taking an ACE inhibitor and/or angiotensin receptor blocker at follow-up ( Figure 2D) ; no difference was observed in the medically managed group.
Renal artery revascularization and subsequent HF control
There was no difference in all-cause mortality between the patients who underwent PTRA and those treated medically [RR adjusted for age of 1.2 (CI 0.6-2.6), P = 0.6]. However, PTRA with stenting was associated with significantly better HF control. More subjects in the intervention group improved their NYHA class (42% versus 18%; P < 0.04), with a lower average NYHA class (1.9 ± 0.8 versus 2.6 ± 1, P < 0.05) ( Figure 3A ). There were significantly fewer patients with NYHA class III/IV HF upon follow-up ( Figure  3B ). The proportion of patients treated with PTRA and stenting who subsequently required hospitalization for HF was significantly less than those medically treated ( Figure 4A) , with a 5-fold reduction in the average number of hospitalizations ( Figure 4B ), the majority of which were HF related (≈80%). This difference in hospitalization for HF occurred soon after the procedure ( Figure 4C ). When adjusting for age, sex, renal function, blood pressure, medication use and NYHA class, the strongest predictor of a subsequent hospitalization for HF was whether or not a pa- Fig. 2 . Renal artery revascularization associated with a reduction in the number of antihypertensive medications (A), a fall in systolic blood pressure (B), without a difference in overall renal function (C), compared to those managed medically. In patients with a left ventricular ejection fraction <40% (D), PTRA with stenting was associated with an increase in the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB). * P < 0.05. Fig. 3 . Renal artery revascularization associated with a reduction in the average NYHA functional class (A) and the proportion with NHYA class III/IV symptoms (B) compared to medical therapy alone. * P < 0.05. Fig. 4 . Renal artery revascularization associated with a reduction in the proportion of patients hospitalized for heart failure (HF) (A) and the overall average number of hospitalizations (B) compared to medical therapy alone. The time to first HF hospitalization was significantly increased in the PTRA with stenting group (C). * P < 0.05.
tient had undergone PTRA with stenting. Similar trends were seen even in those who had only unilateral RAS, with a lower rate of subsequent hospitalization for HF, 12% (PTRA with stenting group) versus 45% (medical group), P < 0.01.
Discussion
Our study demonstrates that HF affects close to one-third of patients with significant hypertension and chronic kidney disease referred for revascularization of atherosclerotic RAS. The presence of HF in subjects with atherosclerotic RAS identifies a very high-risk cohort with decreased survival. The majority of these patients had relative preservation of left ventricular systolic function and echocardiographic evidence of diastolic dysfunction, suggesting that their HF may be hypertension mediated. In these patients, renal artery revascularization resulted in improved blood pressure control, a higher likelihood of experiencing an improvement in renal function and improved HF control (as evidenced by the more common use of ACE inhibitors and angiotensin II receptor blockers, improvement in HF functional class and a reduction in HF hospitalizations). However, renal artery revascularization did not impact all-cause mortality.
Our results extend previous case reports/series [10, 12, 18, 19] suggesting a benefit of renal artery revascularization over medical management in patients with RAS and HF, with respect to subsequent cardiovascular outcomes. Despite considerable differences in renal, cardiac and blood pressure outcomes between the groups, no differences were observed in all-cause mortality. A possible explanation for the lack of survival benefit relates to the fact that this is a cohort of patients with a high prevalence of atherosclerotic vascular disease, and any benefit from improved control of HF may be overcome by their inherent high risk for progression of their atherosclerotic disease. Indeed, a previous study of patients with RAS and hypertension identified renal dysfunction, reduced LVEF and significant RAS as strong predictors of 4-year survival [28] . While the majority of the patients in our study had relative preservation of left ventricular systolic function, this might not have resulted in a significant survival benefit, as previous community-based studies have indicated that the mortality rates of patients with normal ejection fraction are approaching those of patients with reduced ejection fraction HF, although the cause of death in the former group is not necessarily related to cardiovascular causes. This is particularly apparent in elderly patients with multiple comorbidities [29] [30] [31] . In our study, the significant difference in age between the groups may have further impacted our survival data.
Atherosclerotic RAS and HF share common risk factors, and their association may simply reflect a high atherosclerotic burden in the cardiovascular patient population [4, 7] . However, RAS may contribute to the pathogenesis of HF through a number of potential mechanisms, most importantly chronic systemic hypertension leading to diastolic dysfunction (frequently present in RAS subjects), which, when coupled with impaired pressure natriuresis, may lead to acute hypertension-associated 'flash' pulmonary oedema [8, 9, 32] . Our results demonstrated that in patients with RAS and chronic kidney disease, diastolic dysfunction was universally present, with a greater degree of diastolic dysfunction seen in those subjects with HF. The benefits of HF control likely were facilitated through improved blood pressure control and a reduction in the neurohumoral abnormalities associated with haemodynamically significant RAS. Indeed, PTRA appeared to have facilitated the increased frequency of use of modulators of the renin-angiotensin system, agents known to benefit cardiovascular structure and function in patients with cardiac disease, including HF [33] [34] [35] .
Our study has some inherent limitations by its design. The study is retrospective with studies performed as part of routine medical care. A serum creatinine ≥2 mg/dL likely selects for a cohort with a greater overall atherosclerotic disease burden and a higher degree of bilateral disease. HF may not be as prevalent in those patients with RAS and either normal renal function or more modest degrees of renal insufficiency. Our study focused on percutaneous renal artery revascularization. While most renal artery lesions are amenable to percutaneous revascularization in the modern era, our results cannot be generalized to a surgical approach. While a slight difference in age was the only identifiable difference between the intervention and medical treatment groups, it is likely that other factors (apart from the degree of hypertension, medication use, rates of other cardiovascular interventions, including coronary revascularizations and HF characteristics) may have contributed to the choice of treatment strategy. Despite these limitations, our results suggest that renal revascularization in patients with renovascular disease and HF is associated with improved HF control. Serial echocardiographic assessments evaluating the impact of PTRA and medical therapy on changes in left ventricular structure and function would be of interest, but were not available in sufficient subjects here at comparable time points to allow for a meaningful analysis.
PTRA with stenting is considered first line therapy for treatment of renovascular hypertension resistant to medical therapy, and preservation of renal function in patients with atherosclerotic RAS. These patients are commonly poor surgical candidates due to multiple comorbidities and advanced age [36] . To date, only three randomized trials have compared renal artery revascularization to medical management in a prospective fashion [37] [38] [39] . The end-points focused on blood pressure control and preservation of renal function, and did not include cardiovascular outcomes. The current ACC/AHA class I recommendations [20] for renal artery intervention in the setting of haemodynamically significant RAS and recurrent unexplained HF, and/ or sudden unexplained episodes of pulmonary oedema, are based on expert opinion, single case reports, small case series and three retrospective uncontrolled case series of limited follow-up [12, 40, 41] . The results of a large prospective multicenter randomized trial, Cardiovascular Outcomes in Renal Artery Lesions (CORAL) evaluating medical therapy versus medical therapy and renal artery revascularization for patients with hypertension and RAS, are expected in the next 3-4 years [42] . While im-portant insights may result from this study to address the question of RAS and HF, notable exclusion factors in CORAL (such as HF hospitalization within 3 months, LVEF <30% and a serum creatinine >3 mg/dL) may reduce the specificity of these results to a RAS/HF group. The Angioplasty and STent for Renal Artery Lesions (ASTRAL) trial in the UK [43] is also designed to compare medical therapy to stenting in hypertension and RAS. In this study, there is a pre-defined cardiac sub-study (although not necessarily focused on patients with HF), including cardiac imaging and neurohormonal measures. This study may provide definitive support for the appropriateness and value of renal artery revascularization for atherosclerotic RAS in the setting of HF. Until the results of these trials become available, our results provide further support for current recommendations calling for renal revascularization of patients with significant RAS and concomitant, unexplained HF.
In conclusion, HF is prevalent in a cohort of patients with hypertension, renal dysfunction and atherosclerotic RAS who are referred for renal artery revascularization. The presence of HF may be an independent predictor of survival in this population. Renal arterial revascularization could improve HF control and may reduce HF hospitalizations, at least in part, likely due to better blood pressure control and subsequent ability to use ACE inhibitors or angiotensin II receptor blockers.
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